Domperidone in Treating Patients With Gastrointestinal Disorders
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Digestive System Disorder
- Dyspepsia
- Esophagitis
- Gastroesophageal Reflux Disease
- Gastroparesis
- Heartburn
- Nausea and Vomiting
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 16 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVES: I. To provide treatment with domperidone to patients >= 16 years of age where, according to the investigators' judgment, a prokinetic effect is needed for the relief of gastrointestinal (GI) motility disorders. OUTLINE: Patients receive domperidone orally (PO) thrice daily (TID) ...
PRIMARY OBJECTIVES: I. To provide treatment with domperidone to patients >= 16 years of age where, according to the investigators' judgment, a prokinetic effect is needed for the relief of gastrointestinal (GI) motility disorders. OUTLINE: Patients receive domperidone orally (PO) thrice daily (TID) or four times daily (QID). Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up for at least 30 days.
Tracking Information
- NCT #
- NCT01696734
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Mehnaz Shafi M.D. Anderson Cancer Center
Get Well Soon